Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
Low-Molecular-Weight Collagen Peptides (LMWCP) similarly regulate the Wnt/-catenin pathway
Unlabeled vials lead to dangerous confusion, especially if you work with multiple peptides like BPC-157 , TB-500 , or semaglutide simultaneously
139 SatariM.HajipoorB.HosseinkhaniS.AbdolmalekiP
US$ 28.32
US$ 21.04
US$ 21.46
US$ 28.56
US$ 24.81
US$ 21.38
US$ 23.35
US$ 26.95